Kornimate/medical-research-clean huggingface dataset:
mirnas in high grade serous ovarian cancer

Conditions: High Grade Serous Ovarian Cancer

Summary: high grade serous ovarian cancer represents the gynecological malignancy with the highest incidence of mortality. decision-making tools are currently limited to the use of standard imaging modalities and analysis of serum biomarkers, such as ca 125, which often have low specificity and sensitivity. recently, a growing research interest has been aimed at so-called circulating micrornas (mirnas). indeed, it has been observed that mirnas are abundantly present in all biological fluids and play the key role of messengers in intercellular communication. cancer cells have a rapid turnover which results in a continuous release of nucleic acids and vesicles derived from the tumor itself, such as the tumor cells themselves that separate from the tumor mass to enter the bloodstream. given their important role as modulators of gene expression, in order to preserve their integrity, mirnas are encapsulated in specific vesicles, in order to prevent their degradation by the enzymes present in biological fluids. in this context, the chance of monitoring the expression levels of specific mirnas represents a very interesting option both for an early diagnosis and for monitoring the clinical response to pharmacological treatment. currently, there are no non-invasive approaches to monitor the clinical outcome in real time, while the identification of circulating biomarkers would allow prompt intervention, possibly modifying the pharmacological management in case of progression.


Eligibility criteria:
inclusion criteria: * age\>18 * histological diagnosis of epithelial ovarian cancer * patients eligible for surgery * patients followed in the clinical care pathway c / o oncological gynecology (surgery and follow up) * informed consent exclusion criteria: * patients with hcv, hbv and hiv * patients with other malignancies diagnosed less than 5 years prior to the diagnosis of ovarian malignancy * ovarian metastases of primary neoplasms of other organs * presence of ascites for non-neoplastic causes

Keywords: mirnas
minimally invasive protocols for the treatment and control of caries lesions in children and adolescents

Conditions: Dental Caries

Summary: this multicenter longitudinal interventional study aims to evaluate the effectiveness of four minimally invasive protocols for the prevention and control of dental caries in children and adolescents. in the first phase, approximately 50,000 children aged 6 to 12 years from five brazilian cities will undergo dental screening and receive preventive oral health interventions. in the second phase, 2,500 children diagnosed with active caries will be treated with different interventions, depending on lesion severity. all participants will be followed up every three months for 24 months.

this study is a multicenter longitudinal interventional trial coordinated by the brazilian society of pediatric dentistry (aboped) in five brazilian cities: são paulo, curitiba, brasília, fortaleza, and belém. the aim is to assess the effectiveness of four evidence-based minimally invasive protocols for preventing and managing dental caries in children and adolescents, and to propose a replicable public health model for pediatric oral care. in the first phase, approximately 50,000 children aged 6-12 years will undergo dental screening using the international caries detection and assessment system (icdas). all children will receive health literacy activities, oral hygiene instructions, toothbrushes, fluoride toothpaste (1,100 ppm), and a single application of fluoride varnish (duraphat®) to permanent molars and incisors. children identified with active caries lesions (icdas 1-6) will be considered for the second phase. a total of 2,500 participants will be selected and allocated to one of the following four intervention protocols based on clinical diagnosis: protocol 1: single application of fluoride varnish for prevention. protocol 2: four weekly applications of fluoride varnish for active white spot lesions, followed by quarterly applications. protocol 3: high-viscosity glass ionomer art sealants (for icdas 3), with quarterly fluoride varnish. protocol 4: conventional atraumatic restorative treatment (art) with glass ionomer (for icdas 4-6), plus quarterly fluoride varnish. participants will be followed up every three months over a 24-month period.

Eligibility criteria:
inclusion criteria: * children aged between 6 and 12 years at the time of enrollment * presence of at least one erupted permanent first molar * diagnosis of active caries lesions classified according to icdas (scores 1 to 6) * written informed consent signed by a legal guardian and assent signed by the child * ability to attend quarterly follow-up visits over a 24-month period exclusion criteria: * children requiring endodontic treatment or presenting extensive pulpal involvement * presence of systemic diseases or medical conditions that contraindicate dental care * known allergy to any material used in the study (fluoride varnish, high-viscosity glass ionomer cement) * participation in other clinical dental studies that could interfere with the outcomes
transarterial chemoembolization versus proton beam radiotherapy for the treatment of hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular

Summary: patients with liver tumor burden that exceeds milan criteria are considered to receive one of the following locoregional treatments: transarterial chemoembolization (tace), radiofrequency ablation (rfa), percutaneous ethanol injection and proton beam radiation (pbr). the goals of these treatments are to control tumor growth, to downstage tumor size to meet milan criteria, and to improve survival. patients who exceed the milan criteria benefit from tumor downstaging as a result of treatment. patients who meet milan criteria benefit from tumor control to bridge them to liver transplantation. tace is considered the most common locoregional treatment that is used to treat hepatocellular carcinoma (hcc). proton beam radiotherapy has been used in treating hcc in a few centers across the globe. phase i and ii trials showed a satisfactory safety and efficacy results. loma linda university medical center is one of these pioneering centers that use proton beam as a treatment for hcc. this is the first randomized trial in the medical field that will compare head-to-head the efficacy of tace versus proton beam in treating hcc patients.


Eligibility criteria:
inclusion criteria: 1. patients are candidates to receive both proton beam and tace 2. patients with no evidence of metastasis or macrovascular invasion 3. patients with tumor burden that meets san francisco criteria exclusion criteria: 1. patients who are candidates for surgical resection 2. patients with lesion \< 2 cm 3. patients who have contraindication to receive either tace or proton 4. patients with serum alpha fetoprotein \> 500 5. patients with metastasis or macrovascular invasion 6. patients treated previously for hcc by any locoregional treatment 7. patients with prior liver transplant 8. patients with child class c 9. patients with meld score of \> 25 10. patients with other comorbid diseases that may impact survival 11. patients with ongoing alcohol intake 12. patients with active sepsis 13. patients with gastrointestinal bleeding within a week 14. patients unwilling to sign informed consent form 15. patients with history of noncompliance

Keywords: transarterial chemoembolization carcinoma, hepatocellular proton beam radiotherapy
yoga therapy in treating patients with malignant brain tumors

Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Meningioma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Choroid Plexus Tumor; Adult Diffuse Astrocytoma; Adult Ependymoblastoma; Adult Ependymoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Grade II Meningioma; Adult Medulloblastoma; Adult Meningeal Hemangiopericytoma; Adult Mixed Glioma; Adult Oligodendroglioma; Adult Papillary Meningioma; Adult Pineal Gland Astrocytoma; Adult Pineoblastoma; Adult Pineocytoma; Adult Supratentorial Primitive Neuroectodermal Tumor (PNET); Recurrent Adult Brain Tumor

Summary: this clinical trial studies yoga therapy in treating patients with malignant brain tumors. yoga therapy may improve the quality of life of patients with brain tumors

primary objectives: i. to estimate the participation rate, accrual, adherence, and retention to a yoga trial in patients with malignant brain tumors. secondary objectives: i. to obtain estimates of the variability of self-reported fatigue, distress (i.e., depression, anxiety), sleep disturbance, cognitive function, and health-related quality of life from baseline to the end of the intervention at 6 (post-onsite intervention) and 12 weeks (post-full intervention). ii. to obtain preliminary estimates of the efficacy of a yoga intervention in patients with malignant brain tumors on the outcomes of fatigue, distress, and cognitive function. iii. to standardize the cancer-specific yoga protocol for use with brain tumor patients. outline: patients participate in yoga classes comprising postures, deep relaxation, breathing practices, and meditation twice weekly for 75 minutes during weeks 1-6. patients then practice yoga at home twice weekly for 45 minutes during weeks 7-12. after completion of study treatment, patients are followed up periodically for 4-5 months.

Eligibility criteria:
inclusion criteria: signed protocol specific informed consent are diagnosed with a malignant brain tumor (grades ii-iv) able to start the on-site yoga intervention within 1 week of first radiation treatment are physically able to attend the intervention classes (eastern cooperative oncology group \[ecog\] performance status rating 0-2) able to understand written and spoken english have no medical contraindications reported by the attending physician exclusion criteria: have practiced yoga on a regular basis (at least once a week) within the past 4 weeks to recruit participants who are not already regularly practicing yoga; given that the benefits of yoga are likely more immediate than long-term, however, we will enroll participants who have previously had a yoga practice
feasibility and effectiveness of distributing micronutrient sprinkles to reduce prevalence of anemia

Conditions: Anemia

Summary: the objective of this study is to test the feasibility and effectiveness of distributing micronutrient sprinkles to 6-20 month old children participating in an integrated maternal and child health and nutrition program in rural haiti. the micronutrient sprinkles have been formulated to prevent or treat anemia in 6-23 month old children. effectiveness in reducing the prevalence of anemia will be assessed.

anemia is highly prevalent among infants and young children in haiti and throughout the world. low intakes of several micronutrients contribute to this problem. it is very difficult to meet the micronutrient needs of infants and young children without substantial amounts of animal-source foods; such foods are not affordable for most families in many poor communities. micronutrient sprinkles are a novel approach to meeting children's needs. the sprinkles are packed in sachets containing a daily ration, and are intended to be used in the home and "sprinkled" directly on the children's food. earlier trials have shown the efficacy of the sprinkles for preventing and treating anemia under controlled conditions. the current study tests the feasibility and effectiveness when sprinkles are distributed in the programmatic context of a us title ii food aid distribution program, a context that is common in many countries that receive assistance from the united states agency for international development and other donors. the study also includes the development and dissemination of educational messages to motivate and enable caregivers to use the sprinkles properly. based on previous efficacy trials no side-effects are anticipated, but the study also monitors for unanticipated side-effects. comparison: since effectiveness of the sprinkles distributed as part of a take-home ration has not been established, this study employed a randomized controlled design. randomization occurred at the level of the food distribution point (place where community members gather to receive food rations). groups were assigned to receive either the take home ration (usual program practice) or the take home ration and the sprinkles. families receiving only food rations at the control sites will receive sprinkles along with their food ration immediately after data collection is complete. the design was also consistent with the program necessity of a gradual roll-out of this new intervention. the prevalence of anemia among target-age children will be compared between groups that receive a two-month supply of micronutrient sprinkles with their take-home food ration, and those that do not.

Eligibility criteria:
inclusion criteria: * 6-20 months old at time of recruitment * family receives food rations at world vision-haiti's food distribution points exclusion criteria: * severe anemia at time of recruitment (hemoglobin \<7.0 g/dl)

Keywords: anemia infant nutrition dietary supplements randomized controlled trials evaluation studies haiti
therapeutic modulation of the intestinal creatine kinase system in inflammatory bowel disease (ibd)

Conditions: Colitis, Ulcerative

Summary: this study plans to learn more about the effects that creatine monohydrate has on disease activity in ulcerative colitis. creatine is a substance that is naturally produced by the body and is found in foods, such as meat and fish. creatine helps to provide energy to some body tissues, such as the colon. in the colon, this energy allows cells to form a tight barrier between molecules in digested food and bacteria and the body's infection-fighting cells within the colon underneath this barrier. if the barrier becomes "leaky" molecules may pass through and lead to inflammation. this "leakiness" may contribute to the colon inflammation seen in ulcerative colitis.


Eligibility criteria:
inclusion criteria: * male or female patients aged 18-70 years old with mild- to moderately-active uc that extends at least 15 cm proximal to the anal verge (i.e. not proctitis) as defined by a mayo score of 3-10, with an endoscopic subscore ≥ 1. * allowed concomitant medications will include mesalamine compounds if used for at least 8 weeks and at a stable dose for at least 4 weeks, as well as thiopurines (azathioprine, 6-mercaptopurine) if used at a stable dose for at least 3 months. exclusion criteria: * abnormal baseline laboratory tests: * albumin \< 3.0 g/dl * alt, ast, total bilirubin, or alkaline phosphatase \> 1.5 x uln * potassium \ 5.5 mmol/l * creatinine or cystatin c \> uln * wbc ≤ 3000 * platelets ≤ 105 * hemoglobin ≤ 10g/dl * positive stool test for clostridium difficile, ova and parasites, or routine stool culture * pregnancy (as confirmed by urine pregnancy test at study outset), stated desire to become pregnant during the study period, or refusal/inability to use effective methods of contraception during the study period. * concomitant major comorbidities (renal, hepatic, cardiac, pulmonary or malignancy) to include any medical conditions requiring therapeutic anti-coagulation or anti-platelet therapy. * diagnosis of severe uc (mayo score \> 10) * evidence or history of toxic megacolon * patients who received anti-tnf agents within 3 months of screening, or who used oral or rectal corticosteroids within 4 weeks of screening will be excluded. * use of over-the-counter herbal or dietary supplements (excluding vitamin and minerals) two weeks prior to or during the study period. * use of known nephrotoxic medications (including non-steroidal anti-inflammatory drugs (nsaids), cyclosporin a, tacrolimus, aminoglycoside antibiotics, diuretics, angiotensin converting enzyme (ace) inhibitors, or angiotensin receptor blockers) 2 weeks prior to or during the study period * prior surgical bowel resections (excluding appendectomy) * local or systemic complications or other pathological states requiring therapy with corticosteroids and/or immunosuppressive agents.

Keywords: colitis, ulcerative inflammatory bowel diseases
balloon angioplasty vs. cutting balloon angioplasty of femoropopliteal arteries- a randomized controlled trial

Conditions: Peripheral Vascular Disease; Intermittent Claudication; Atherosclerosis; Angioplasty

Summary: the purpose of this study to compare balloon angioplasty (pta) vs. cutting balloon angioplasty (cb-pta) in terms of patency and postintervention inflammation in peripheral artery disease.

balloon angioplasty is a minimal invasive technique for treatment of superficial femoropoliteal artery obstructions. despite high initial success rate and an acceptably low complication rate, long-term-results are disappointing as restenosis may frequently occur. one of the hypothesis for the differences in the reported patency rates is that the amount of vessel trauma correlates directly to the prognosis (restenosis) of the treated vessel wall segment. with the introduction of cutting balloons the problems of elastic recoil and residual stenosis might be resolved, by reduction of vessel wall trauma, vessel wall inflammation and consequently reduced neointima formation. the promising results especially in coronary arteries led us to initiate a rct comparing primary pta vs. cb-pta for treatment of femoropoliteal obstructions in patients with intermittent claudication or critical limb ischemia.

Eligibility criteria:
inclusion criteria: * severe intermittent claucication (fontaine stage iib)or limb ischemia, femoropoliteal stenosis/occlusion up to 5 cm length exclusion criteria: * previous bypass surgery at the site of treatment, * previous stent placement at or immediatly adjacent to target lesion, * history of anti-platelet-therapy intolerance or adverse reaction to heparin, * bleeding diathesis, * creatinine \> 2,5 mg/dl, * active bacterial infection, * allergy to contrast media

Keywords: peripheral vascular disease percutaneous transluminal angioplasty cutting balloon balloon angioplasty randomized controlled trial restenosis inflammation
the effect of clinical pilates training on balance and postural control of people with parkinson's disease.

Conditions: Parkinson Disease

Summary: many studies showed that clinical pilates exercises has positive effects on static and dynamic balance of different populations. it was suggested that this type of exercise reduce the risk of falls and physical damage. it also helps prevention of kyphotic posture. parkinson's patients have both balance and postural problems but no study investigated the effect of clinical pilates exercises for this population. the aim of this study is to investigate the effects of clinical pilates exercise program on postural control and balance in individuals with parkinson's disease.

the patients will be randomly assigned into two groups: clinical pilates (cp) group and classic physiotherapy (cf) group. both groups will be treated for 8 weeks. the evaluation of the patients will be done before the beginning of exercise program and will be repeated at the end. static balance of patients will be evaluated with single leg stance test and tandem stance test, dynamic balance with functional reach test (frt) and 30 second chair stand test. postural control and balance will also be evaluated with berg balance scale and functional capacity by timed up and go test. symptom severity and treatment complications of the patients will be evaluated with united parkinson's disease rating scale.

Eligibility criteria:
inclusion criteria: * stage 2-3 of modified hoehn \& yahr scale * 26 or\> 26 points from the mini mental test * having at least 2 years parkinson disease exclusion criteria: * serious mental and psychological disorder * significant musculoskeletal disorders * lower extremity deformation * having another neurological disease * drug or dose change during treatment
phase ii study of valproate and doxorubicin in malignant mesothelioma

Conditions: Malignant Mesothelioma

Summary: the purpose of this study is to determine the response rate to the combination of doxorubicin and valproate acid in patients with mm failing after at least one previous chemotherapy regimen including platinum derivatives .


Eligibility criteria:
inclusion criteria: * histological diagnosis of malignant mesothelioma * unresectable or inoperable malignant mesothelioma failing after at least one prior chemotherapy regimen including platinum derivatives (cisplatin or carboplatin) * at least one evaluable or measurable ct-lesion * availability for participating in the detailed follow-up of the protocol * signed informed consent exclusion criteria: * patients who are candidates for surgery with curative intent * patient who were previously treated with anthracyclin derivatives * performance status \< 60 on the karnofsky scale * a history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix and cured malignant tumour (more than 5-year disease free interval) * a history of prior hiv infection * polynuclear cells \< 2,000/mm³ * platelet cells \< 100,000/mm³ * abnormal coagulation tests (aptt, ptt, prothrombin time) and/or decreased fibrinogen * serum bilirubin \>1.5 mg/100 ml * transaminases more than twice the normal range * serum creatinine \> 1.5 mg/100 ml * recent myocardial infarction (less than 3 months prior to date of diagnosis) * congestive cardiac failure (ejectional fraction of the left ventricle \< 50%) or uncontrolled cardiac arrhythmia * uncontrolled infectious disease * active epilepsy needing a specific treatment * concomitant treatment with imao, carbamazepine, mefloquine, phenobarbital, primidone, phenytoïn, lamotrigine, zidovudine * pregnancy or refusal to use active contraception * a known allergy to valproate acid and/or doxorubicin * serious medical or psychological factors which may prevent adherence to the treatment schedule

Keywords: mesothelioma valproate doxorubicin chemotherapy phase ii
prevention of pacemaker lead induced tricuspid regurgitation by transesophageal echo guided implantation registry

Conditions: Tricuspid Valve Insufficiency; Pacemaker Complication; Echocardiography, Transesophageal

Summary: registry for patients undergoing pacemaker/icd implantation including a transtricuspid lead with and without intraprocedural transesophageal echocardiography to evaluate risk factors for lead induced tricuspid regurgitation.

lead induced tricuspid regurgitation is a common finding after pacemaker/icd implantation. transesophageal echocardiography (tee) might be used to guide lead implantations in order to prevent tricuspid regurgitation. in this registry, patients undergoing pacemaker/icd implantation including a transtricuspid lead are enrolled. while in most patients lead implantation is guided by fluroscopy, in some patients lead implantation is guided by tee in addition to fluroscopy. aims of this registry: evaluation of * incidence of lead induced tricuspid regurgitation * mortality and morbidity of lead induced tricuspid regurgitation * identification of risk factors for lead induced tricuspid regurgitation * influence of the lead position within the tricuspid valve on the incidence of lead induced tricuspid regurgitation * prevention of lead induced tricuspid regurgitation by tee-guided lead implantation

Eligibility criteria:
inclusion criteria: * indication for pacemaker/icd implantation including a transtricuspid lead according to guidelines exclusion criteria: * pre-existing rv lead * pre-existing tr \>2